"The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
Allopurinol acts on purine catabolism without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. The degree of this decrease is dose dependent.
Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in man. Allopurinol is metabolized to the corresponding xanthine analogue, oxypurinol (alloxanthine), which also is an inhibitor of xanthine oxidase.
Reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol and oxypurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving allopurinol for treatment of hyperuricemia is usually in the range of 0.3 to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of allopurinol. These values are far below the saturation levels, at which point their precipitation would be expected to occur (above 7 mg/dL).
The renal clearance of hypoxanthine and xanthine is at least 10 times greater than that of uric acid. The increased xanthine and hypoxanthine in the urine have not been accompanied by problems of nephrolithiasis. There are isolated case reports of xanthine crystalluria in patients who were treated with oral allopurinol.
The action of oral allopurinol differs from that of uricosuric agents, which lower the serum uric acid level by increasing urinary excretion of uric acid. Allopurinol reduces both the serum and urinary uric acid levels by inhibiting the formation of uric acid. The use of allopurinol to block the formation of urates avoids the hazard of increased renal excretion of uric acid posed by uricosuric drugs.
Following intravenous administration in six healthy male and female subjects, allopurinol was rapidly eliminated from the systemic circulation primarily via oxidative metabolism to oxypurinol, with no detectable plasma concentration of allopurinol after 5 hours post dosing. Approximately 12% of the allopurinol intravenous dose was excreted unchanged, 76% excreted as oxypurinol, and the remaining dose excreted as riboside conjugates in the urine. The rapid conversion of allopurinol to oxypurinol was not significantly different after repeated allopurinol dosing. Oxypurinol was present in systemic circulation in much higher concentrations and for a much longer period than allopurinol; thus, it is generally believed that the pharmacological action of allopurinol is mediated via oxypurinol. Oxypurinol was primarily eliminated unchanged in urine by glomerular filtration and tubular reabsorption, with a net renal clearance of about 30 mL/min.
To compare the pharmacokinetics of allopurinol and oxypurinol between intravenous (i.v.) and oral (p.o.) administration of ALOPRIM (allopurinol sodium) for Injection, a well-controlled, four-way crossover study was conducted in 16 male healthy volunteers. ALOPRIM (allopurinol sodium) for Injection was administered via an intravenous infusion over 30 minutes. Pharmacokinetic parameter estimates of allopurinol (mean ± S.D.) following single i.v. and p.o. administration of ALOPRIM (allopurinol sodium) for Injection are summarized as follows:
Administration of ALOPRIM™ (allopurinol sodium) for Injection
|Allopurinol Parameters||100 mg i.v.||300 mg i.v.||100 mg p.o.*||300 mg p.o.|
|Cmax (µg/mL)||1.58 ± 0.22||5.12 ± 0.82||0.53 ± 0.10||1.35 ± 0.49|
|Tmax (hr)||0.50||0.50||1.00 ± 0.39||1.67 ± 0.96|
|T1/2 (hr)||1.00 ± 0.46||1.21 ± 0.33||0.98 ± 0.43||1.32 ± 0.32|
|AUC0→• (hr•µg/mL)||1.99 ± 0.63||7.10 ± 1.28||1.03 ± 0.24||3.69 ± 0.96|
|CL (mL/min/kg)||12.2 ± 3.11||9.94 ± 2.36|
|Vss (L/kg)†||0.84 ± 0.13||0.87 ± 0.13|
|Fabsolute(%)††||48.8 ± 19.7||52.7 ± 13.1|
|* n = 7
† Volume of Distribution (Steady-State)
†† Absolute Bioavailability
Oxypurinol was measurable in the plasma within 10 to 15 minutes following the administration of ALOPRIM (allopurinol sodium) for Injection. Pharmacokinetic parameter estimates of oxypurinol following i.v. and p.o. administration of ALOPRIM (allopurinol sodium) for Injection are shown below:
Administration of ALOPRIM™ (allopurinol sodium) for
|Oxypurinol Parameters||100 mg i.v.||300 mg i.v.||100 mg p.o.||300 mg p.o.|
|C max (µg/mL)||2.20 ± 0.31||6.18 ± 0.78||2.36 ± 0.30||6.36 ± 0.83|
|Tmax (hr)||3.89 ± 1.41||4.16 ± 1.2||3.10 ± 1.49||4.13 ± 1.35|
|T1/2(hr)||24.1 ± 5.4||23.5 ± 4.5||24.9 ± 8.4||23.7 ± 3.4|
|AUC0→• (hr•µg/mL)||80 ± 24||231 ± 54||83 ± 22||245 ± 49|
|Frelative (%)||107 ± 25||108 ± 9|
|* Relative Bioavailability|
In general, the ratio of the area under the plasma concentration vs time curve (AUC0→•.) between oxypurinol and allopurinol was in the magnitude of 30 to 40. The C max and AUCAUC0→• for both allopurinol and oxypurinol following i.v. administration of ALOPRIM (allopurinol sodium for injection) (allopurinol sodium) for Injection were dose proportional in the dose range of 100 to 300 mg. The half-life of allopurinol and oxypurinol was not influenced by the route of ALOPRIM (allopurinol sodium) for Injection administration. Oral and intravenous administration of ALOPRIM (allopurinol sodium) for Injection at equal doses produced nearly superimposable oxypurinol plasma concentration vs time profiles, and the relative bioavailability of oxypurinol (Frelative) was approximately 100%. Thus, the pharmacokinetics and plasma profiles of oxypurinol, the major pharmacological component derived from allopurinol, are similar after intravenous and oral administration of ALOPRIM (allopurinol sodium) for Injection.
A compassionate plea trial was conducted from 1977 through 1989 in which 718 evaluable patients with malignancies requiring treatment with cytotoxic chemotherapy, but who were unable to ingest or retain oral medication, received i.v. ALOPRIM (allopurinol sodium) for Injection in the U.S. Of these patients, 411 had established hyperuricemia and 307 had normal serum urate levels at the time that treatment was initiated. Normal serum uric acid levels were achieved in 68% (reduction of serum uric acid was documented in 93%) of the former, and were maintained throughout chemotherapy in 97% of the latter. Because of the study design, it was not possible to assess the impact of the treatment upon the clinical outcome of the patient groups.
Last reviewed on RxList: 5/28/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Aloprim Information
- Aloprim Drug Interactions Center: allopurinol sodium iv
- Aloprim Side Effects Center
- Aloprim FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.